# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-17T15:10:32.053583
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 15200 in / 5360 out
**Response SHA256:** 4dc5e7d4afb665b0

---

## Referee Report: “State Minimum Wage Increases and the HCBS Provider Supply Crisis”

### Summary and contribution
The paper asks an important and policy-relevant question: do state minimum wage increases (MW) reduce access to Medicaid Home and Community-Based Services (HCBS) by constraining provider supply? The premise—HCBS providers face regulated reimbursement and therefore limited ability to pass through wage shocks—is compelling and fits the broader “regulated-price sector” lens that is underexplored in the MW literature.

Empirically, the paper builds a novel state-by-year panel from (near-)universe T-MSIS claims linked to NPPES and estimates staggered DiD effects using modern estimators (Callaway–Sant’Anna; Sun–Abraham), supplemented by TWFE, DDD, placebo, and randomization inference.

The headline results are directionally negative but imprecise for provider counts (CS ATT ≈ -0.048 log points, SE 0.069) and larger for beneficiaries served (CS ATT ≈ -0.123, SE 0.078; TWFE elasticity ≈ -0.61, SE 0.29). The main “economic” takeaway is an intensive-margin channel (fewer beneficiaries per provider rather than provider exit).

Overall: strong topic, strong data ambition, and generally appropriate modern DiD choices. The biggest remaining issues are (i) clarity/consistency of estimands and interpretation across TWFE vs CS-DiD, (ii) whether the state-year design can credibly isolate MW effects from correlated policy changes (especially reimbursement and pandemic-era changes), and (iii) whether the main outcomes (provider counts; beneficiary-months) validly measure “access” and “supply” in ways that match the paper’s claims.

---

# 1. FORMAT CHECK

**Length**
- The LaTeX source appears to be comfortably **≥ 25 pages** in 12pt, 1.5 spacing, with figures/tables and appendices. Approximate rendered length likely **30–45 pages** depending on table/figure sizes. **PASS**.

**References**
- The introduction cites key MW and DiD methodology papers (Card & Krueger; Cengiz et al.; Dube; Callaway–Sant’Anna; Sun–Abraham; Roth; Goodman-Bacon) and some Medicaid/provider participation papers.
- However, key literatures are missing or under-engaged (see Section 4 below), especially: regulated reimbursement/pass-through in Medicaid/LTSS, home care labor supply, HCBS-specific provider participation, and the “few treated clusters / inference” literature relevant to 51-state panels.

**Prose (paragraph form, not bullets)**
- Major sections are written in paragraphs. Bullets/numbered lists appear appropriately in appendix/data processing. **PASS**.

**Section depth**
- Introduction: multiple substantive paragraphs. Background/Data/Strategy/Results/Discussion/Conclusion: each has multiple paragraphs. **PASS**.

**Figures**
- Figures are included via `\includegraphics`. In LaTeX source review I cannot verify axis labels/visibility. The captions suggest proper content; you should ensure each figure has labeled axes, units, and sample notes. **Provisionally PASS** (but confirm in rendered PDF).

**Tables**
- Summary statistics table has real numbers. Other main tables are `\input{tables/...}`; cannot verify content here, but the text reports coefficients/SEs. Make sure each table includes N, fixed effects, clustering, and clear notes. **Provisionally PASS**.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### a) Standard errors for every coefficient
- In-text reporting includes SEs for many headline estimates (good).
- Because key tables are external inputs, the referee cannot verify that **every coefficient** in every table has SEs/CI/p-values.
- **Action item:** Ensure every regression table reports **SEs in parentheses** (or CIs), and clearly states clustering level and number of clusters.

### b) Significance testing / inference
- You report p-values in places; CS-DiD uses multiplier bootstrap; you also do Fisher randomization inference.
- This is a strength. However:
  - Inference with **51 clusters** can still be fragile. Consider reporting **wild cluster bootstrap p-values** (e.g., Cameron, Gelbach & Miller) for key TWFE/DDD regressions, or randomization-inference-based p-values for the primary estimand as well (not only TWFE).
  - Clarify whether CS-DiD confidence intervals are **uniform** or **pointwise** (you say pointwise in figure notes). For event studies, top journals increasingly expect **simultaneous/uniform** bands or at least a joint pre-trends test with appropriate adjustments.

### c) 95% confidence intervals for main results
- Event study figures mention 95% CIs. Main text often reports coefficient + SE + p-value but not explicit CI.
- **Action item (easy):** For the **main two outcomes** (providers and beneficiaries), report **95% CIs** in the abstract and main tables (or at least in main text).

### d) Sample sizes (N) reported for all regressions
- Summary stats: N=306 state-years.
- But regression N is not verifiable in the external tables. Also DDD stacked panel implies N=612 unit-years.
- **Action item:** Every regression table should list **N**, and (ideally) **#states / #clusters**.

### e) DiD with staggered adoption
- You explicitly recognize TWFE bias and use **Callaway–Sant’Anna** with **never-treated** states + Sun–Abraham. **PASS**, and this is a major strength.
- Two concerns to address:
  1. **Treatment definition vs estimand mismatch.** CS-DiD uses first ≥$0.50 MW increase (binary adoption), while TWFE uses continuous log(MW). These answer different questions. The paper currently mixes them in interpretation (“elasticity” vs “ATT of adoption”) but then compares magnitudes informally. This needs cleaner organization: pick a *primary estimand* and make the other clearly complementary.
  2. **“Never-treated” validity.** Many “never-treated” states still have MW changes < $0.50 or indexation, and local MW changes. You partly address with “at or near federal.” You should show robustness to alternative definitions: (i) excluding states with any MW change; (ii) using “not-yet-treated” controls in CS-DiD (allowed under assumptions) as sensitivity; (iii) dose-response CS-DiD variants if feasible.

### f) RDD
- Not applicable. **N/A**.

**Bottom line on methodology:** No fatal inference failures are visible, and you use modern staggered DiD appropriately. The main “critical” fixes are reporting (CIs, N, cluster counts) and strengthening inference credibility with few clusters and event-study multiple-testing concerns.

---

# 3. IDENTIFICATION STRATEGY

### Credibility of identification
The paper’s identification claim is: conditional on state FE + year FE, treated and never-treated states would have followed parallel trends in HCBS provider supply absent MW increases.

Strengths:
- You use event studies and report flat pre-trends (good).
- You recognize non-random policy adoption and frame identification around parallel trends (good).
- You attempt to address confounding via ARPA exclusion and DDD with non-HCBS providers.

Key vulnerabilities (need more work):
1. **Policy endogeneity and correlated shocks.** Minimum wage increases correlate with:
   - Medicaid generosity and HCBS policy expansions;
   - reimbursement rate changes (beyond ARPA, including state-driven rate updates);
   - managed care transitions in LTSS;
   - COVID-era labor market shocks and state policy bundles.
   The ARPA exclusion helps but is not a general solution. The DDD helps only if non-HCBS providers share the same confounding shocks *and* are otherwise valid controls (see below).

2. **DDD validity.** Using “non-HCBS Medicaid providers” (CPT-billing physicians/specialists) as a within-state control presumes that confounders move HCBS and non-HCBS similarly absent MW effects. That is not obviously true: HCBS trends are affected by LTSS demand, aging, waiver slots, self-directed program rules, and home care agency regulation—none of which necessarily affect physician participation. As a result, the DDD may not “difference out” the main confounders and could even introduce new ones (differential exposure to managed care, telehealth, etc.).
   - I would reframe DDD as a **placebo / suggestive** test, not as a definitive confounding solution, unless you can argue convincingly that the dominant confounds are general Medicaid provider shocks that affect both groups.

3. **Measurement of “provider supply” and “access.”**
   - Provider counts from claims measure “billing activity,” not active capacity, staffing, or willingness to accept new clients. This is acknowledged, but the paper still makes strong “access” claims.
   - Beneficiary-months are not unique beneficiaries; they reflect intensity and may mechanically change with coding/claims practices or shifts between FFS and MCO encounter completeness.
   - Since T-MSIS encounter data quality varies by state and over time, differential reporting improvements could correlate with MW policy (e.g., higher-capacity states both raise MW and improve encounter submissions). You partially discuss reporting lags in 2024; but cross-state differential reporting quality within 2018–2023 is still a serious threat.

### Assumptions and diagnostics
- **Parallel trends:** You rely on event-study pre-trends. But you also note the 2019 cohort has only one pre-year—weak for diagnosing pre-trends.
  - Add **pre-trend tests by cohort** (where feasible) and/or show results excluding the early-treated cohort(s) with minimal pre-period.
  - Consider adding **Roth (2022/2023) style sensitivity** to violations of parallel trends (e.g., HonestDiD bounds) for the event-study estimates.

### Placebos and robustness
What you have: non-HCBS placebo, ARPA-state exclusion, Sun–Abraham comparison, randomization inference.

What’s missing / recommended:
- **Alternative control groups:** e.g., restrict to a “donor pool” of states with similar pre-trends, or implement synthetic DiD / augmented SCM at the state level as a robustness check (even if underpowered).
- **Border-county design** is not feasible with state-year outcomes, but you could do a **border-state pair** check using bordering states’ differences (though still coarse).
- **Negative control outcomes** within HCBS that should not respond to MW (hard, but possible): e.g., outcomes tied to services less labor-intensive or more clinician-driven (if separable by code).

### Do conclusions follow from evidence?
- The intensive-margin story (beneficiaries fall more than provider counts) is plausible and consistent with point estimates.
- However, the paper sometimes states results as if established when the preferred CS-DiD estimates are not statistically distinguishable from zero and are fairly imprecise. Top journals will require more disciplined language:
  - Emphasize **“consistent with”** and quantify uncertainty.
  - Avoid over-relying on TWFE significance when you correctly argue CS-DiD is preferred.

### Limitations
- You do acknowledge several limitations (good). I would elevate measurement/reporting quality and policy bundling concerns more prominently, and make clear what can/cannot be interpreted as “access.”

---

# 4. LITERATURE (MISSING REFERENCES + BibTeX)

You cite several core DiD and MW papers, but the positioning relative to (i) health care provider supply/payment, (ii) direct care labor markets, and (iii) inference with few clusters could be strengthened. Below are specific, high-return additions.

## A. DiD / event-study inference and sensitivity (beyond what you cite)
1) **Rambachan & Roth (Honest DiD)**
- Why: You rely on pre-trend “flatness” with limited pre-periods; HonestDiD provides sensitivity/bounds that are increasingly expected in top journals.
```bibtex
@article{RambachanRoth2023,
  author = {Rambachan, Ashesh and Roth, Jonathan},
  title = {A More Credible Approach to Parallel Trends},
  journal = {Review of Economic Studies},
  year = {2023},
  volume = {90},
  number = {5},
  pages = {2555--2591}
}
```

2) **de Chaisemartin & D’Haultfoeuille (staggered DiD)**
- Why: You cite 2020 working paper-style reference; ensure the published version is cited and clarify estimator choice relative to theirs.
```bibtex
@article{deChaisemartinDHaultfoeuille2020,
  author = {de Chaisemartin, Cl{\'e}ment and d'Haultf{\oe}uille, Xavier},
  title = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year = {2020},
  volume = {110},
  number = {9},
  pages = {2964--2996}
}
```

3) **Few clusters / wild bootstrap**
- Why: 51 clusters is borderline; reporting wild-cluster bootstrap p-values is good practice.
```bibtex
@article{CameronGelbachMiller2008,
  author = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {Review of Economics and Statistics},
  year = {2008},
  volume = {90},
  number = {3},
  pages = {414--427}
}
```

## B. Minimum wage literature most relevant to your mechanism (outside options, sectoral reallocation)
You cite Cengiz and Dube. Consider adding:
- **Meer & West (dynamic employment effects)**
```bibtex
@article{MeerWest2016,
  author = {Meer, Jonathan and West, Jeremy},
  title = {Effects of the Minimum Wage on Employment Dynamics},
  journal = {Journal of Human Resources},
  year = {2016},
  volume = {51},
  number = {2},
  pages = {500--522}
}
```

- **Clemens & Wither (minimum wage, low-skilled labor markets)**
```bibtex
@article{ClemensWither2019,
  author = {Clemens, Jeffrey and Wither, Michael},
  title = {The Minimum Wage and the Great Recession: Evidence of Effects on the Employment and Income Trajectories of Low-Skilled Workers},
  journal = {Journal of Public Economics},
  year = {2019},
  volume = {170},
  pages = {53--67}
}
```

## C. Medicaid payment, provider participation, and pass-through (closer to HCBS/LTSS)
You cite Clemens (2014) and some provider participation papers, but the LTSS / home care setting has a sizable literature on wages, staffing, and reimbursement.

- **Pass-through in Medicaid/home care wages** (examples; you should pick the closest ones to your exact setting after a targeted search):
  - A well-known strand studies nursing home staffing responses to Medicaid reimbursement; for home care, there is also evidence on reimbursement and wages/turnover. If you can’t find HCBS-specific pass-through, at least cite nursing home pass-through/staffing papers and explain the mapping.

One foundational Medicaid reimbursement-to-outcomes paper you *should* cite if discussing reimbursement constraints generally:
```bibtex
@article{ClemensGottlieb2017,
  author = {Clemens, Jeffrey and Gottlieb, Joshua D.},
  title = {In the Shadow of a Giant: Medicare's Influence on Private Physician Payments},
  journal = {Journal of Political Economy},
  year = {2017},
  volume = {125},
  number = {1},
  pages = {1--39}
}
```
Why: It’s central on administered prices and spillovers/pass-through logic; helps motivate your “regulated price” mechanism more rigorously (even if Medicare-focused).

Also consider citing work on Medicaid physician fee changes and participation (you have Decker 2012; add the ACA “fee bump” evaluations if not already in your .bib):
```bibtex
@article{Polsky2015,
  author = {Polsky, Daniel and Candon, Molly and Saloner, Brendan and Wissoker, Doug and Hempstead, Katherine and Kenney, Genevieve M.},
  title = {Changes in Primary Care Access Between 2012 and 2014 for New Medicaid Patients},
  journal = {JAMA},
  year = {2015},
  volume = {314},
  number = {20},
  pages = {2152--2159}
}
```
Why: While not HCBS, it anchors “payment policy affects access/provider behavior” in a widely cited setting and helps with framing.

**Important:** The paper will be much stronger if you add *HCBS/home care-specific* causal evidence on reimbursement → supply/wages/turnover. I cannot responsibly invent exact citations without checking; you should do a focused search (keywords: “home care”, “personal care”, “Medicaid”, “reimbursement”, “wages”, “turnover”, “pass-through”, “direct care workforce”) and integrate 3–6 closest papers.

## D. Data / measurement: T-MSIS validity
Given the centrality of T-MSIS encounters/claims, it is important to cite documentation/validation work on T-MSIS completeness and cross-state comparability (beyond CMS technical notes). If there are peer-reviewed validations, add them; if not, cite CMS DQ Atlas and explain how you address differential completeness.

---

# 5. WRITING QUALITY (CRITICAL)

### a) Prose vs bullets
- Major sections are in paragraphs; bullets mainly in appendix methods. **PASS**.

### b) Narrative flow
- The Introduction is strong: concrete hook (waiting lists), clear mechanism, and contribution statement.
- Where flow weakens is in the transition from “provider supply crisis” to “what exactly is measured.” You should bring forward (in Intro or early Data) the key limitation that “providers” are *billing NPIs* and “beneficiaries” are *beneficiary-months*, and argue why these are credible proxies for access/capacity.

### c) Sentence quality and style
- Generally clear, active voice, good signposting.
- Some claims are too definitive relative to the uncertainty (especially when CS-DiD is imprecise). Tighten modal language and align rhetoric with preferred estimand.

### d) Accessibility for non-specialists
- Good explanation of institutional background.
- Econometric intuition is mostly there, but you should simplify the “two estimands” issue: many readers will be confused by CS-DiD (binary adoption) vs TWFE (continuous) giving different magnitudes/significance.

### e) Tables
- Since tables are in external files, ensure the rendered tables are self-contained:
  - define outcomes precisely (“beneficiary-months” vs “unique beneficiaries”);
  - list fixed effects, clustering, weights (if any), and N/clusters;
  - include mean of outcome in control group for scale.

---

# 6. CONSTRUCTIVE SUGGESTIONS (to increase credibility and impact)

## A. Make one estimand primary and redesign presentation around it
Right now the paper’s narrative sometimes treats TWFE and CS-DiD as co-equal while simultaneously warning TWFE is biased. For a top journal, choose:

- **Option 1 (recommended): Primary = CS-DiD/Sun–Abraham event-study on discrete adoption**, and move TWFE continuous elasticities to secondary/appendix as descriptive dose-response.
- **Option 2: Primary = continuous treatment effects**, but then you need a design that supports continuous/staggered “dose” robustly (e.g., generalized DiD with continuous treatments; or treat MW changes as “events” with size bins and estimate heterogeneous effects by change magnitude).

## B. Strengthen the “regulated reimbursement constraint” mechanism empirically
The paper’s mechanism hinges on reimbursement not adjusting when MW increases. You partially address via ARPA exclusion, but top-journal readers will want a direct test:

1. **Measure HCBS reimbursement generosity** at the state-year level (even imperfect proxies):
   - HCBS spending per beneficiary; payment per claim; average paid per beneficiary-month; or rate schedules if obtainable.
2. **Test interaction:** MW effect should be more negative where reimbursement is lower or grows slowly.
   - e.g., `MW × (low reimbursement)` or `MW × reimbursement growth`.
3. **Event-study of payments per beneficiary/provider** around MW increases:
   - Do payments rise (suggesting reimbursement adjustments) or not?

Even a noisy proxy is informative if the interaction aligns with theory.

## C. Address T-MSIS measurement/completeness concerns head-on
Because you use encounter/claims data across all states, differential reporting is a first-order threat.

Concrete steps:
- Include state fixed effects (you do) and year effects (you do), but also consider:
  - **State-specific linear trends** as a robustness check (with caveats about overfitting in staggered designs; present cautiously).
  - Drop states with known poor encounter completeness or big discontinuities (based on CMS DQ Atlas) and show robustness.
  - Use outcomes less sensitive to encounter completeness (e.g., provider counts may be more robust than beneficiary-months; but even provider counts depend on reporting).

## D. Revisit the DDD design / choose a better within-state comparison
“Non-HCBS Medicaid providers” may not be the right control for HCBS-specific confounders. Consider alternative within-state controls:
- Providers serving **services with similar billing/encounter processes** but higher wages (e.g., certain outpatient therapy providers), or
- Within HCBS: compare **more MW-exposed codes** (personal care attendant) vs **less MW-exposed codes** (clinician-driven behavioral health) if your HCPCS grouping allows it. This “internal HCBS reweighting” might be more credible than physician CPT providers.

## E. Improve power/precision where possible
State-year panels are noisy. You already have state-month data (N=3,672). Consider making **monthly** the primary frequency with:
- month-by-year fixed effects (or year-month FE),
- treatment dated at effective month (many increases occur Jan 1; some mid-year),
- CS-DiD on monthly data (if computationally feasible and treatment timing is properly coded).
This can materially increase precision—though be careful about serial correlation and the interpretation (and potential reporting artifacts at monthly frequency).

## F. Clarify “beneficiaries served” and interpret magnitudes carefully
You currently translate a 6.1% reduction into “3,000 fewer people receiving care in a given month,” but your outcome is beneficiary-months and may not map 1:1 to unique people.

- Provide both:
  1) beneficiary-months (intensity),
  2) unique beneficiaries per year (if possible), or average monthly unique beneficiaries.
- Consider also analyzing **services volume** (claims, hours/units if available) to triangulate “access/capacity.”

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Important question at the intersection of MW policy and Medicaid LTSS access.
- Novel administrative data construction linking T-MSIS to NPPES.
- Correct awareness of staggered DiD pitfalls; uses Callaway–Sant’Anna and Sun–Abraham.
- Good suite of supporting checks: event studies, placebo, ARPA exclusion, randomization inference.
- Clear institutional background and a plausible mechanism with direct policy relevance.

### Critical weaknesses (salvageable)
1. **Estimand inconsistency and over-interpretation**: TWFE vs CS-DiD tell different stories (significance differs); narrative should follow the preferred estimator and align claims with uncertainty.
2. **Confounding policy bundles / measurement validity**: MW increases correlate with other state policy shifts; T-MSIS cross-state reporting comparability is a major identification threat that needs deeper treatment.
3. **DDD control group validity**: non-HCBS physicians may not be the right within-state control to net out confounders relevant to HCBS.
4. **Reporting/inference transparency**: ensure all tables show N, clusters, SEs, and add 95% CIs (and ideally wild cluster bootstrap p-values).

### Specific, high-priority revisions
- Re-center the paper around one primary estimand (preferably CS-DiD/Sun–Abraham) and downgrade TWFE to complementary.
- Add reimbursement interaction tests (or at minimum stronger evidence that reimbursement did not adjust contemporaneously with MW).
- Add a serious T-MSIS data-quality section: state exclusions/robustness based on encounter completeness; demonstrate results are not driven by reporting artifacts.
- Add HonestDiD (Rambachan–Roth) or similar sensitivity for parallel trends, and/or cohort-by-cohort pretrend diagnostics.
- Expand and sharpen literature positioning, including inference-with-clusters and administered prices/pass-through.

---

DECISION: MAJOR REVISION